Skip to content
2000
Volume 22, Issue 3
  • ISSN: 1573-4072
  • E-ISSN: 1875-6646

Abstract

Background/Introduction

Cancer, a disease with substantial worldwide health consequences, is driven by the uncontrolled division and spread of cells. A combination of genetics, environmental factors, and personal lifestyle choices influences its development. Cancer remains a significant global health challenge, driving the need for new therapeutic compounds. Helfer, an edible insect, contains bioactive compounds that may provide a natural approach to reducing cancer progression through dietary intake. Rich in proteins, fatty acids, and bioactive compounds, this insect shows promise in its anti-inflammatory and antioxidant properties.

Aim

Cancer, characterized by uncontrolled cell growth, poses global health challenges, while natural bioactive compounds offer a cost-effective and less toxic alternative by targeting cancer pathways. This current study aims to identify potential bioactive compounds from silk warm pupa and screen their bioactivity against various cancers through approaches.

Objective

Currently, available cancer medications are often associated with a range of side effects. Plant-derived compounds present a promising alternative for cancer treatment, offering the potential for fewer side effects. This research aims to identify the most effective bioactive lead molecule for future drug development in the fight against various types of cancer.

Methods

To evaluate the therapeutic potential of metabolites from Helfer, various techniques were used. Molecular docking analysis were conducted to assess the binding affinity and stability of the compounds with cancer-related targets such as EGFR, FGFR, VEGFR1, and mTOR, revealing their inhibitory potential. ADMET analysis predicted the pharmacokinetic properties, including absorption, toxicity, and drug-likeness. In contrast, QSAR analysis forecasted the biological activity of the compounds, helping to quantify their effectiveness in triggering specific biological responses.

Results and Discussion

The molecular docking studies showed promising results, with several bioactive compounds from Helfer exhibiting strong binding affinities to EGFR, FGFR, VEGFR1, and mTOR, suggesting significant inhibitory potential against these cancer-related targets. ADMET analysis further supported these findings by indicating favorable pharmacokinetic properties, such as good absorption, low toxicity, and minimal risk of side effects. QSAR analysis predicted high biological activity for the compounds, reinforcing their potential as effective anticancer agents.

Conclusion

The study identifies Helfer as a significant source of bioactive agents like 2-(Dimethylamino) ethyl (9Z,12Z)-octadeca-9,12-dienoate, Echinulin, and Phorbol 12-tiglate 13-decanoate, with promising anticancer activity. analysis indicates these compounds could inhibit key cancer-related targets like EGFR, FGFR, VEGFR1, and mTOR. Further and experimental studies are needed to validate their therapeutic efficacy and safety.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cbc/10.2174/0115734072366437250317081705
2025-03-27
2026-03-05

  • From This Site

    /content/journals/cbc/10.2174/0115734072366437250317081705
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. MathersC.D. History of global burden of disease assessment at the World Health Organization.Arch. Public Health20207817710.1186/s13690‑020‑00458‑3 32850124
     [Google Scholar]
  2. SungH. FerlayJ. SiegelR.L. LaversanneM. SoerjomataramI. JemalA. BrayF. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J. Clin.202171320924910.3322/caac.21660 33538338
     [Google Scholar]
  3. KochH. WilhelmM. RuprechtB. BeckS. FrejnoM. KlaegerS. KusterB. Phosphoproteome profiling reveals molecular mechanisms of growth-factor-mediated kinase inhibitor resistance in EGFR-overexpressing cancer cells.J. Proteome Res.201615124490450410.1021/acs.jproteome.6b00621 27794612
     [Google Scholar]
  4. MalekanM. EbrahimzadehM.A. Vascular endothelial growth factor receptors [VEGFR] as target in breast cancer treatment: Current status in preclinical and clinical studies and future directions.Curr. Top. Med. Chem.2022221189192010.2174/1568026622666220308161710 35260067
     [Google Scholar]
  5. LiX. ZhouJ. WangX. LiC. MaZ. WanQ. PengF. New advances in the research of clinical treatment and novel anticancer agents in tumor angiogenesis.Biomed. Pharmacother.202316311480610.1016/j.biopha.2023.114806 37163782
     [Google Scholar]
  6. EstradaC.C. MaldonadoA. MallipattuS.K. Therapeutic inhibition of VEGF signaling and associated nephrotoxicities.J. Am. Soc. Nephrol.201930218720010.1681/ASN.2018080853 30642877
     [Google Scholar]
  7. HuangX.L. KhanM.I. WangJ. AliR. AliS.W. ZahraQ.A. KazmiA. LolaiA. HuangY.L. HussainA. BilalM. LiF. QiuB. Role of receptor tyrosine kinases mediated signal transduction pathways in tumor growth and angiogenesis: New insight and futuristic vision.Int. J. Biol. Macromol.202118073975210.1016/j.ijbiomac.2021.03.075 33737188
     [Google Scholar]
  8. ZhangN. LiY. Receptor tyrosine kinases: Biological functions and anticancer targeted therapy.MedComm202346e44610.1002/mco2.446 38077251
     [Google Scholar]
  9. HuangJ. ChenS. ShiY. LiC-H. WangX.J. LiF.J. WangC.H. MengQ.H. ZhongJ.N. LiuM. WangZ.M. Epigallocatechin gallate from green tea exhibits potent anticancer effects in A-549 non-small lung cancer cells by inducing apoptosis, cell cycle arrest and inhibition of cell migration.J. Balkan Union Oncol.201722614221427 29332333
     [Google Scholar]
  10. AcevedoV.D. IttmannM. SpencerD.M. Paths of FGFR-driven tumorigenesis.Cell Cycle20098458058810.4161/cc.8.4.7657 19182515
     [Google Scholar]
  11. KatohM. FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis.Int. J. Mol. Med.201638131510.3892/ijmm.2016.2620 27245147
     [Google Scholar]
  12. HuP. BaderG. WigleD.A. EmiliA. Computational prediction of cancer-gene function.Nat. Rev. Cancer200771233410.1038/nrc2036 17167517
     [Google Scholar]
  13. BarillotE. CalzoneL. HupeP. VertJ-P. ZinovyevA. Computational systems biology of cancer.FLCRC Press Boca Raton2013
     [Google Scholar]
  14. TomuleasaC. TiguA.B. MunteanuR. MoldovanC.S. KegyesD. OnaciuA. GuleiD. GhiaurG. EinseleH. CroceC.M. Therapeutic advances of targeting receptor tyrosine kinases in cancer.Signal Transduct. Target. Ther.20249120110.1038/s41392‑024‑01899‑w 39138146
     [Google Scholar]
  15. MoshawihS. LimA.F. ArdiantoC. GohK.W. KifliN. GohH.P. JarrarQ. MingL.C. Target-based small molecule drug discovery for colorectal cancer: A review of molecular pathways and in silico studies.Biomolecules202212787810.3390/biom12070878 35883434
     [Google Scholar]
  16. BranchG. Molecular mechanisms of tumor cell resistance to the fgfr kinase inhibitor. PhD Thesis, Nat. Res. Inst.2023
     [Google Scholar]
  17. Oliveira-FerrerL. LeglerK. Milde-LangoschK. Role of protein glycosylation in cancer metastasis.Semin. Cancer Biol.201714115210.1016/j.semcancer.2017.03.002
     [Google Scholar]
  18. NandiS. DeyR. SamadderA. SaxenaA. SaxenaA.K. Natural Sourced inhibitors of EGFR, PDGFR, FGFR and VEGFRMediated signaling pathways as potential anticancer agents.Curr. Med. Chem.202229221223410.2174/0929867328666210303101345 33655823
     [Google Scholar]
  19. ZareiP. GhasemiF. The application of artificial intelligence and drug repositioning for the identification of fibroblast growth factor receptor inhibitors: A review.Adv. Biomed. Res.202413910.4103/abr.abr_170_23 38525398
     [Google Scholar]
  20. MaddeboinaK. YadaB. KumariS. McHaleC. PalD. DurdenD.L. Recent advances in multitarget-directed ligands via in silico drug discovery.Drug Discov. Today202429310390410.1016/j.drudis.2024.103904 38280625
     [Google Scholar]
  21. BaskaranC. RamachandranM. Computational molecular docking studies on anticancer drugs.Asian Pac. J. Trop. Dis.20122S734S73810.1016/S2222‑1808(12)60254‑0
     [Google Scholar]
  22. AlbrattyM. Quantitative structure–activity relationship modeling and docking of some synthesized bioactive oxopyrolidines against Staphylococcus aureus.J. Saudi Chem. Soc.202226410150910.1016/j.jscs.2022.101509
     [Google Scholar]
  23. NevesB.J. BragaR.C. Melo-FilhoC.C. Moreira-FilhoJ.T. MuratovE.N. AndradeC.H. QSAR-based virtual screening: Advances and applications in drug discovery.Front. Pharmacol.20189127510.3389/fphar.2018.01275 30524275
     [Google Scholar]
  24. AntonicelliA. CafarottiS. IndiniA. GalliA. RussoA. CesarioA. LococoF.M. RussoP. MaininiA.F. BonifatiL.G. NosottiM. SantambrogioL. MargaritoraS. GranoneP.M. DutlyA.E. EGFR-targeted therapy for non-small cell lung cancer: Focus on EGFR oncogenic mutation.Int. J. Med. Sci.201310332033010.7150/ijms.4609 23423768
     [Google Scholar]
  25. GridelliC. RossiA. CarboneD.P. GuarizeJ. KarachaliouN. MokT. PetrellaF. SpaggiariL. RosellR. Non-small-cell lung cancer.Nat. Rev. Dis. Primers2015111500910.1038/nrdp.2015.9 27188576
     [Google Scholar]
  26. LiuT-C. JinX. WangY. WangK. Role of epidermal growth factor receptor in lung cancer and targeted therapies.Am. J. Cancer Res.201772187202 28337370
     [Google Scholar]
  27. De GreefD. BartonE.M. SandbergE.N. CroleyC.R. PumarolJ. WongT.L. DasN. BishayeeA. Anticancer potential of garlic and its bioactive constituents: A systematic and comprehensive review.Semin. Cancer Biol.202121926410.1016/j.semcancer.2020.11.020
     [Google Scholar]
  28. NeogK. SinghH.R. UnniB. SahuA. Analysis of genetic diversity of muga silkworm (Antheraea assamensis, Helfer; Lepidoptera: Saturniidae) using RAPD-based molecular markers.Afr. J. Biotechnol.20109121746175210.5897/AJB10.1745
     [Google Scholar]
  29. DasN. Impact of Muga Silk (Antheraea assamensis) on community livelihood in the Brahmaputra Valley of Assam-India.Am. J. Environ. Protect.2021103596510.11648/j.ajep.20211003.11
     [Google Scholar]
  30. TikaderA. VijayanK. SaratchandraB. Muga silkworm, Antheraea assamensis (Lepidoptera: Saturniidae): An overview of distribution, biology and breeding.Eur. J. Entomol.2013110229330010.14411/eje.2013.096
     [Google Scholar]
  31. SaikiaM. GhoshK. PeiglerR.S. Factors affecting on quality muga silkworm (Antheraea assamensis Helfer) seed crop production: A review.J. Entomol. Zool. Stud.20164806810
     [Google Scholar]
  32. GorbunovaN.A. ZakharovA.N. Edible insects as a source of alternative protein. A review. Theor. pract. meat process.,202162332
     [Google Scholar]
  33. OjhaS. BekhitA.E.D. GruneT. SchlüterO.K. Bioavailability of nutrients from edible insects.Curr. Opin. Food Sci.20214124024810.1016/j.cofs.2021.08.003
     [Google Scholar]
  34. GhoshS. LeeS.M. JungC. Meyer-RochowV.B. Nutritional composition of five commercial edible insects in South Korea.J. Asia Pac. Entomol.201720268669410.1016/j.aspen.2017.04.003
     [Google Scholar]
  35. AielloD. BarberaM. BongiornoD. CammarataM. CensiV. IndelicatoS. MazzottiF. NapoliA. PiazzeseD. SaianoF. Edible insects an alternative nutritional source of bioactive compounds: A review.Molecules202328269910.3390/molecules28020699 36677756
     [Google Scholar]
  36. ZhouY. WangD. ZhouS. DuanH. GuoJ. YanW. Nutritional composition, health benefits, and application value of edible insects: A review.Foods20221124396110.3390/foods11243961 36553703
     [Google Scholar]
  37. SinghA. KumarV. GuhaL. HridyaH. IndirakumarK. MajumdarM. Predisposing factors determining the rearing performance of muga silkworm (Antheraea assamensis Helfer): A review.Int. J. Plant Soil Sci.20223475676210.9734/ijpss/2022/v34i242697
     [Google Scholar]
  38. DeviB. ChutiaM. BhattacharyyaN. Food plant diversity, distribution, and nutritional aspects of the endemic golden silk producing silkworm, Antheraea assamensis: A review.Entomol. Exp. Appl.2021169323724810.1111/eea.13021
     [Google Scholar]
  39. ChoudhuryM. ParbinS. PeguS. BanikS. DasP. Comparative analysis of natural bioactive metabolites of the indigenous host plants of Muga silkworm for antioxidant and antibacterial properties against swine diseases.Indian J. Pharm. Sci.20238516475
     [Google Scholar]
  40. SinghY.D. DasD. DasS. SwainK.D. PradhanS. BabuP.J. Pharmacological activities of limonin from Khasi Mandarin as therapeutic applications.Pharmacol. Res. Mod. Chin. Med.2022510018110.1016/j.prmcm.2022.100181
     [Google Scholar]
  41. Bitencourt-FerreiraG. de AzevedoW.F. Molegro virtual docker for docking. Methods Mol. Biol.,2019205314916710.1007/978‑1‑4939‑9752‑7_10.
     [Google Scholar]
  42. de AzevedoW.F. Docking Screens For Drug Discovery.Springer201910.1007/978‑1‑4939‑9752‑7
     [Google Scholar]
  43. GramaticaP. On the development and validation of QSAR models.Methods Mol. Biol.201393049952610.1007/978‑1‑62703‑059‑5_21 23086855
     [Google Scholar]
  44. SurajambikaR.R. PalanikarasuP. 2D-QSAR modeling, docking, synthesis and in-vitro evaluation of novel flavone derivatives] as anticancer agents.Curr. Bioact. Compd.2024203e22052321715310.2174/1573407219666230522112102
     [Google Scholar]
  45. FariedA. KurniaD. FariedL. UsmanN. MiyazakiT. KatoH. KuwanoH. Anticancer effects of gallic acid isolated from Indonesian herbal medicine, Phaleria macrocarpa (Scheff.) Boerl, on human cancer cell lines.Int. J. Oncol.200730360561310.3892/ijo.30.3.605 17273761
     [Google Scholar]
  46. AliM. MohammedN. AlnaqeebM.A. HassanR.A.H. AhmadH.S.A. Toxicity of echinulin from Aspergillus chevalieri in rabbits.Toxicol. Lett.198948323524110.1016/0378‑4274(89)90049‑0 2781591
     [Google Scholar]
  47. CarrollA.R. CoppB.R. DavisR.A. KeyzersR.A. PrinsepM.R. Marine natural products.Nat. Prod. Rep.201936112217310.1039/C8NP00092A 30663727
     [Google Scholar]
  48. PereiraA.G. Fraga-CorralM. García-OliveiraP. Jimenez-LopezC. Lourenço-LopesC. CarpenaM. OteroP. GullónP. PrietoM.A. Simal-GandaraJ. Culinary and nutritional value of edible wild plants from northern Spain rich in phenolic compounds with potential health benefits.Food Funct.202011108493851510.1039/D0FO02147D 33034610
     [Google Scholar]
  49. RodosyF.B. AzadM.A.K. HalderS.K. LimonM.B.H. JamanS. LataN.A. SarkerM. RiyaA.I. The potential of phytochemicals against epidermal growth factor receptor tyrosine kinase (EGFRK): An insight from molecular dynamic simulations.J. Biomol. Struct. Dyn.20244252482249310.1080/07391102.2023.2207656 37154806
     [Google Scholar]
  50. El KhatabiK. AlaqarbehM. RehmanH.M. AjanaM.A. LakhlifiT. BouachrineM. Computational investigation of potent EGFR inhibitors from flavonoid-based phytochemical constituents of caralluma europaea as pancreatic cancer agents. Physical.Chem. Res.202412963974
     [Google Scholar]
  51. ChandrikaB.B. SteephanM. KumarT.R.S. SabuA. HaridasM. Hesperetin and Naringenin sensitize HER2 positive cancer cells to death by serving as HER2 Tyrosine Kinase inhibitors.Life Sci.2016160475610.1016/j.lfs.2016.07.007 27449398
     [Google Scholar]
  52. CavasottoC.N. OrtizM.A. AbagyanR.A. PiedrafitaF.J. In silico identification of novel EGFR inhibitors with antiproliferative activity against cancer cells.Bioorg. Med. Chem. Lett.20061671969197410.1016/j.bmcl.2005.12.067 16413185
     [Google Scholar]
  53. NasserA.A. EissaI.H. OunM.R. El-ZahabiM.A. TaghourM.S. BelalA. SalehA.M. MehanyA.B.M. LueschH. MostafaA.E. AfifiW.M. RoccaJ.R. MahdyH.A. Discovery of new pyrimidine-5-carbonitrile derivatives as anticancer agents targeting EGFR WT and EGFR T790M.Org. Biomol. Chem.202018387608763410.1039/D0OB01557A 32959865
     [Google Scholar]
  54. YadavI. SinghH. KhanM. ChaudhuryA. RaghavaG.P.S. AgarwalS. EGFRIndb: Epidermal growth factor receptor inhibitor database.Anticancer. Agents Med. Chem.201414792893510.2174/1871520614666140323203140
     [Google Scholar]
  55. Masudur Rahman MunnaM. Touki Tahamid TusarM. Sajnin ShantaS. Hossain AhmedM. Sarafat AliM. Unveiling promising phytocompounds from Moringa oleifera as dual inhibitors of EGFR(T790M/C797S) and VEGFR-2 in non-small cell lung cancer through in silico screening, ADMET, dynamics simulation, and DFT analysis.J. Genet. Eng. Biotechnol.202422310040610.1016/j.jgeb.2024.100406 39179328
     [Google Scholar]
  56. RizviS.M. MudagalM.P. BoregowdaS.S. HussainT. Al HagbaniT. AbdallahM.H. KhafagyE-S. HussainA. AdamF.A.Y. LilaA.S.A. The flavonoid hesperidin methyl chalcone as a potential therapeutic agent for cancer therapy: Molecular docking, in vitro cytotoxicity, and in vivo antitumor activity.Arab. J. Chem.20231610476910.1016/j.arabjc.2023.104769
     [Google Scholar]
  57. NakagawaK. GaronE.B. SetoT. NishioM. Ponce AixS. Paz-AresL. ChiuC.H. ParkK. NovelloS. NadalE. ImamuraF. YohK. ShihJ.Y. AuK.H. Moro-SibilotD. EnatsuS. ZimmermannA. Frimodt-MollerB. Visseren-GrulC. ReckM. ChuQ. CortotA. PujolJ-L. Moro-SibilotD. FabreE. LamourC. BischoffH. KollmeierJ. ReckM. KimmichM. Engel-RiedelW. HammerschmidtS. SchütteW. SyrigosK. HoJ.C.M. AuK-H. NovelloS. ArdizzoniA. PaselloG. GregorcV. Del ConteA. GalettaD. TakahashiT. NakagawaK. NishioM. YohK. SetoT. ImamuraF. KumagaiT. HottaK. GotoY. HosomiY. SakaiH. TakiguchiY. KimY.H. KurataT. YamaguchiH. DagaH. OkamotoI. SatouchiM. IkedaS. KasaharaK. AtagiS. AzumaK. KumagaiT. AoeK. KumagaiT. AoeK. HorioY. YamamotoN. TanakaH. WatanabeS. NogamiN. OzakiT. KoyamaR. HirashimaT. KanedaH. TomiiK. FujitaY. SeikeM. NishimuraN. KatoT. IchikiM. SakaH. HiranoK. NakaharaY. SugawaraS. ParkK. KimS-W. MinY.J. LeeH.W. KangJ-H. AnH.J. LeeK.H. KimJ-S. LeeG-W. LeeS.Y. AlexandruA. UdreaA.A. Juan-VidalÓ. Nadal-AlforjaE. Gil-BazoI. Ponce-AixS. Paz-AresL. Rubio-ViqueiraB. Alonso GarciaM. Felip FontE. Fuentes PraderaJ. Coves SartoJ. LinM-C. SuW-C. HsiaT-C. ChangG-C. WeiY-F. ChiuC-H. ShihJ-Y. SuJ. CicinI. GokselT. HarputluogluH. OzyilkanO. HenningI. PopatS. HatcherO. MilehamK. AcobaJ. GaronE. JungG. RajM. MartinW. DakhilS. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): A randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol.201920121655166910.1016/S1470‑2045(19)30634‑5 31591063
     [Google Scholar]
  58. AsiriA. In-silico perspectives on the potential therapeutic aids of hesperetin derivatives for lung cancer.Adv. Life Sci.202411487888610.62940/als.v11i4.3308
     [Google Scholar]
  59. SohelM. SultanaH. SultanaT. Al AminM. AktarS. AliM.C. RahimZ.B. HossainM.A. Al MamunA. AminM.N. DashR. Chemotherapeutic potential of hesperetin for cancer treatment, with mechanistic insights: A comprehensive review.Heliyon202281e0881510.1016/j.heliyon.2022.e08815 35128104
     [Google Scholar]
  60. TanH.K. MoadA.I.H. TanM.L. The mTOR signalling pathway in cancer and the potential mTOR inhibitory activities of natural phytochemicals.Asian Pac. J. Cancer Prev.201415166463647510.7314/APJCP.2014.15.16.6463 25169472
     [Google Scholar]
  61. KhanK. QuispeC. JavedZ. IqbalM.J. SadiaH. RazaS. IrshadA. SalehiB. ReinerŽ. Sharifi-RadJ. Resveratrol, curcumin, paclitaxel and miRNAs mediated regulation of PI3K/Akt/mTOR pathway: Go four better to treat bladder cancer.Cancer Cell Int.202020156010.1186/s12935‑020‑01660‑7 33292283
     [Google Scholar]
  62. JiangH. ShangX. WuH. GautamS.C. Al-HolouS. LiC. KuoJ. ZhangL. ChoppM. Resveratrol downregulates PI3K/Akt/mTOR signaling pathways in human U251 glioma cells.J. Exp. Ther. Oncol.2009812533 19827268
     [Google Scholar]
  63. Karkon-ShayanS. AliashrafzadehH. Dianat-MoghadamH. Rastegar-PouyaniN. MajidiM. ZareiM. moradi-vastegani, S.; Bahramvand, Y.; Babaniamansour, S.; Jafarzadeh, E. Resveratrol as an antitumor agent for glioblastoma multiforme: Targeting resistance and promoting apoptotic cell deaths.Acta Histochem.2023125615205810.1016/j.acthis.2023.152058 37336070
     [Google Scholar]
  64. KhanN. AfaqF. KweonM.H. KimK. MukhtarH. Oral consumption of pomegranate fruit extract inhibits growth and progression of primary lung tumors in mice.Cancer Res.20076773475348210.1158/0008‑5472.CAN‑06‑3941 17389758
     [Google Scholar]
  65. KimH.M. Polyphenolics from Mango (Mangifera indica L.) and Pomegranate (Punica granatum L.) Suppress inflammation in in vivo and in vitro models for Colitis. PhD Thesis, Texas A and M University,2013
     [Google Scholar]
  66. RoyT. BoatengS.T. UddinM.B. Banang-MbeumiS. YadavR.K. BockC.R. FolahanJ.T. Siwe-NoundouX. WalkerA.L. KingJ.A. BuergerC. HuangS. ChamcheuJ.C. The PI3K-Akt-mTOR and associated signaling pathways as molecular drivers of immune-mediated inflammatory skin diseases: Update on therapeutic strategy using natural and synthetic compounds.Cells20231212167110.3390/cells12121671 37371141
     [Google Scholar]
  67. AishwaryaV. SolaipriyaS. SivaramakrishnanV. Role of ellagic acid for the prevention and treatment of liver diseases.Phytother. Res.20213562925294410.1002/ptr.7001 33368795
     [Google Scholar]
  68. NakamuraY. YogosawaS. IzutaniY. WatanabeH. OtsujiE. SakaiT. A combination of indole-3-carbinol and genistein synergistically induces apoptosis in human colon cancer HT-29 cells by inhibiting Akt phosphorylation and progression of autophagy.Mol. Cancer20098110010.1186/1476‑4598‑8‑100 19909554
     [Google Scholar]
  69. MattathiV.W. KumariS. DahiyaP. BhatiaR.K. BhattA.K. MinhasB. KaushikN. Exploring the potential of dietary phytochemicals in cancer therapeutics: Modulating apoptosis and autophagy.Role of Autophagy and Reactive Oxygen Species in Cancer Treatment: Principles and Current Strategies.Springer202430933610.1007/978‑3‑031‑66421‑2_14
     [Google Scholar]
  70. BharathiM. SivamaruthiB.S. KesikaP. ThangaleelaS. ChaiyasutC. In silico screening of potential phytocompounds from several herbs against SARS-CoV-2 indian delta variant b. 1.617. 2 to inhibit the spike glycoprotein trimer.Appl. Sci. (Basel)202212266510.3390/app12020665
     [Google Scholar]
  71. QuideauS. DeffieuxD. Douat-CasassusC. PouységuL. Plant polyphenols: Chemical properties, biological activities, and synthesis.Angew. Chem. Int. Ed.201150358662110.1002/anie.201000044 21226137
     [Google Scholar]
  72. ChengW. LiC. XiaoF. HeJ. LiuL. NiuH. MaJ. Elucidating binding mechanisms of caffeic acid and resveratrol by beta-lactoglobulin: Insights into hydrophobic interactions and complex formation.Food Hydrocoll.202414610926910.1016/j.foodhyd.2023.109269
     [Google Scholar]
  73. PatilR. DasS. StanleyA. YadavL. SudhakarA. VarmaA.K. Optimized hydrophobic interactions and hydrogen bonding at the target-ligand interface leads the pathways of drug-designing.PLoS One201058e1202910.1371/journal.pone.0012029 20808434
     [Google Scholar]
  74. EricksonJ.A. JalaieM. RobertsonD.H. LewisR.A. ViethM. Lessons in molecular recognition: The effects of ligand and protein flexibility on molecular docking accuracy.J. Med. Chem.2004471455510.1021/jm030209y 14695819
     [Google Scholar]
  75. RamírezD. CaballeroJ. Is it reliable to use common molecular docking methods for comparing the binding affinities of enantiomer pairs for their protein target?Int. J. Mol. Sci.201617452510.3390/ijms17040525 27104528
     [Google Scholar]
  76. ZhouY. GoenagaA.L. HarmsB.D. ZouH. LouJ. ConradF. AdamsG.P. SchoeberlB. NielsenU.B. MarksJ.D. Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies.Mol. Cancer Ther.20121171467147610.1158/1535‑7163.MCT‑11‑1038 22564724
     [Google Scholar]
  77. FujiH. QiF. QuL. TakaesuY. HoshinoT. Prediction of ligand binding affinity to target proteins by molecular mechanics theoretical calculation.Chem. Pharm. Bull. (Tokyo)201765546146810.1248/cpb.c16‑00913 28458367
     [Google Scholar]
  78. LiS. LiY. LiuY. WuY. WangQ. JinL. ZhangD. Therapeutic peptides for treatment of lung diseases: Infection, fibrosis, and cancer.Int. J. Mol. Sci.20232410864210.3390/ijms24108642 37239989
     [Google Scholar]
  79. SorrentiV. BuròI. ConsoliV. VanellaL. Recent advances in health benefits of bioactive compounds from food wastes and by-products: Biochemical aspects.Int. J. Mol. Sci.2023243201910.3390/ijms24032019 36768340
     [Google Scholar]
  80. BanwoK. OlojedeA.O. Adesulu-DahunsiA.T. VermaD.K. ThakurM. TripathyS. SinghS. PatelA.R. GuptaA.K. AguilarC.N. UtamaG.L. Functional importance of bioactive compounds of foods with potential health benefits: A review on recent trends.Food Biosci.20214310132010.1016/j.fbio.2021.101320
     [Google Scholar]
  81. PatilB.S. JayaprakashaG.K. Chidambara MurthyK.N. VikramA. Bioactive compounds: Historical perspectives, opportunities, and challenges.J. Agric. Food Chem.200957188142816010.1021/jf9000132 19719126
     [Google Scholar]
  82. MilnerJ.A. Molecular targets for bioactive food components.J. Nutr.200413492492S2498S10.1093/jn/134.9.2492S 15333748
     [Google Scholar]
  83. Perez-GregorioR. Simal-GandaraJ. A critical review of bioactive food components, and of their functional mechanisms, biological effects and health outcomes.Curr. Pharm. Des.201723192731274110.2174/1381612823666170317122913 28317483
     [Google Scholar]
/content/journals/cbc/10.2174/0115734072366437250317081705
Loading
Computational Study on Antheraea assamensis Helfer Metabolites: Targeting FGFR, EGFR, mTOR, and VEGFR1 for Cancer Therapy
Curr. Bioact. Compd. 22, e15734072366437 (2026); https://doi.org/10.2174/0115734072366437250317081705
/content/journals/cbc/10.2174/0115734072366437250317081705
/content/journals/cbc/10.2174/0115734072366437250317081705
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): Antheraea assamensis Helfer; Cancer; drug lead; metabolites; molecular docking; therapeutic potential

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test